LGD 1550

Drug Profile

LGD 1550

Alternative Names: ALRT 1550; ALRT 550; LG 1550

Latest Information Update: 10 Jul 2007

Price : $50

At a glance

  • Originator Allergan; Ligand Pharmaceuticals
  • Class Retinoids; Small molecules
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acne; Cervical cancer; Haematological malignancies; Head and neck cancer; Psoriasis; Solid tumours

Most Recent Events

  • 10 Jul 2007 Discontinued - Phase-II for Solid tumours in USA (PO)
  • 10 Jul 2007 Discontinued - Preclinical for Psoriasis in USA (unspecified route)
  • 10 Jul 2007 Discontinued - Phase-II for Head and neck cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top